Loading
B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.
CD80 (chromosome 3q13.33), also called B7-1, is an immunoglobulin-superfamily costimulatory ligand that acts as the primary auxiliary signal for naive T cells by binding CD28, activating NF-kappa-B and MAPK and raising cytokine production and, through PI3K/AKT, T-cell glucose metabolism; it also binds CTLA-4, a decoy receptor that blocks CD28-mediated priming, and regulates PD-L1/PD-1 interactions (UniProt P33681). In OnCo it appears in the mechanism of the PD-L1 antibodies adebrelimab and sugemalimab, which block PD-L1 binding to PD-1 and to B7-1, and in the mechanism of ipilimumab, which stops CTLA-4 from outcompeting CD28 for B7 ligands during priming.
In plain words · B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.
B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.
The same ligand serves an accelerator (CD28) and a brake (CTLA-4), which is why CTLA-4 blockade increases T-cell priming. PD-L1 antibodies that also free B7-1 restore CD28 costimulation as well as lifting the PD-1 brake.
No product in this corpus aims at CD80 (B7-1) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
First described 1989. Earliest sequence paper UniProt cites for the protein: Freeman G.J. et al, J. Immunol, 1989, "B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells". Source.
The same ligand serves an accelerator (CD28) and a brake (CTLA-4), which is why CTLA-4 blockade increases T-cell priming. PD-L1 antibodies that also free B7-1 restore CD28 costimulation as well as lifting the PD-1 brake.
Query for this target: (TITLE:"CD80" OR ABSTRACT:"CD80" OR TITLE:"B7-1" OR ABSTRACT:"B7-1" OR TITLE:"B7.1" OR ABSTRACT:"B7.1" OR TITLE:"CD28LG" OR ABSTRACT:"CD28LG" OR TITLE:"CD80 molecule" OR ABSTRACT:"CD80 molecule") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD80 (B7-1), not a curated reading list.
Shares CD28, Checkpoint (two meanings), The cancer-immunity cycle, PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag wave5-target.
Shares Checkpoint (two meanings), The cancer-immunity cycle, PD-L1, Immune checkpoint inhibitors and the tag wave5-target.
Shares Checkpoint (two meanings), PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag wave5-target.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Non-small-cell lung cancer and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag wave5-target.
Shares The cancer-immunity cycle and the tag wave5-target.